IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody

Haematologica

Volumn 95, Issue 10, 2010, Pages 1797-1798

  Andrulis, Mindaugas ^a   Capper, David ^a,b   Meyer, Jochen ^a   Penzel, Roland ^a   Hartmann, Christian ^a,b   Zentgraf, Hanswalter ^b   von Deimling, Andreas ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BCR ABL PROTEIN; ISOCITRATE DEHYDROGENASE (NADP); ISOCITRATE DEHYDROGENASE (NADP) 1; JANUS KINASE 2; PROTEIN IDH1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; ERYTHROBLAST; GENE MUTATION; GENE SEQUENCE; GRANULOCYTE; HUMAN; LETTER; MALIGNANT TRANSFORMATION; MEGAKARYOCYTE; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PROTEIN LOCALIZATION; THROMBOCYTOSIS;

AGED; ANTIBODIES, MONOCLONAL; HUMANS; ISOCITRATE DEHYDROGENASE; MIDDLE AGED; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS;

EID: 77957814608     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.024430     Document Type: Letter

References (12)

1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355(23):2452-2466.
2. Beer PA, Delhommeau F, Lecouedic JP, Dawson MA, Chen E, Bareford D, et al. Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115(14):2891-2900.
3. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-474.
4. Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, et al. Distinct clinical and biological characteristics in adult acute myeloid leukemia bearing isocitrate dehydrogenase 1 (IDH1) mutation. Blood. 2010;115(14):2749-2754.
5. Andrulis M, Capper D, Luft T, Hartmann C, Zentgraf H, von Deimling A. Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. Leuk Res. 2010;34(8):1091-1093
6. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
7. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225-234.
8. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2):447-452.
9. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362(4):369-370.
10. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6): 2162-21618.
11. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20(1):245-254.
12. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.